Cellular Origins and Cell and Gene Therapy Catapult collaborate to demonstrate universal automation of CGT manufacturing

Partnership to develop and implement Cellular Origins’ robotic platform Constellation for universal automation of CGT manufacturing at CGT Catapult’s Stevenage Manufacturing Innovation Centre

Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics

Partnership expands spectrum of Secarna’s capabilities for the development of targeted ASOs beyond antibodies and sugar molecules

Exonate appoints Dr Rafiq Hasan as Non-Executive Director

Appointment brings extensive experience in global pharma leadership and progressing ophthalmology drugs to market and further strengthens Board

Closed Loop Medicine appoints Paul Johnson as Non-Executive Director

Appointment of digital healthcare leader to Board to support the Company as it enters next phase of commercial development Co-founder and former CEO of Lemonaid Health, a leading innovator in telemedicine and prescription drug delivery, acquired by 23andMe in 2021

ERS Genomics and IRBM sign CRISPR/Cas9 license agreement

License agreement provides IRBM access to CRISPR gene editing technology to be applied across its drug discovery services offering

Closed Loop Medicine and Pharmanovia commence OptiZest study for their first precision medicine combination therapeutic

Proof-of-Concept study to investigate personalized dose management of first-line anti-hypertensive in improving blood pressure control remotely Key milestone in co-development partnership to combine leading medicine brands with dose optimization technology

Enhanc3D Genomics appoints Hazel Jones as Chief Executive Officer

Cambridge, UK: Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D genome for use in novel target identification and unique patient stratification, announces the appointment of Hazel Jones as Chief Executive Officer, after a successful six-month tenur

PlaqueTec and the Babraham Institute collaborate on early phase target discovery and development

Campus Innovation Award (CIA)-funded project evaluated lead compounds predicted to bind a pro-inflammatory protein discovered by PlaqueTec

ArgusEye closes €2.8 million funding to accelerate bioprocessing

Led by Voima Ventures and co-led by existing investor Eir Ventures Funding will support continued development of Auga sensor system platform to accelerate the bioprocessing workflow from early upstream to late formulation

Stockholm, Sweden

ERS Genomics appoints John E Milad as Chief Executive Officer

Dublin, Ireland: ERS Genomics Limited (‘ERS’), the CRISPR licensing company, announces the appointment of John E Milad as CEO, with immediate effect.

Gyros Protein Technologies introduces Gyrolab Generic Rodent ADA Kit Reagents to support preclinical immunogenicity assessment

Ready-to-use kit expands range of bioanalysis kits, and enables generic detection of immune complexes in rodent samples

Bio-Rad launches three StarBright Red Dyes and expands range of antibody markers conjugated to StarBright Violet Dyes to enhance immunology research

Bio-Rad's Range of StarBright Dyes Conjugated to Highly Validated Antibodies Now Totals 32 Dyes, Providing Greater Choice and Flexibility for Conventional and Full-Spectrum Flow Cytometry in Immunology Research.

PlaqueTec closes $8 million equity financing

The financing was led by Lord Moynihan of Chelsea alongside The Future Fund, with support from existing investors Funding will support ongoing BIOPATTERN trial and build BIOCARTA database to transform the treatment of CAD

Cambridge, UK, 30

Asimov achieves 10x improvement in lentiviral production, launches new stable cell line development service

Stable lentiviral (LV) cell line development service achieves unconcentrated titers >1E9 TU/mL for therapeutic transgenes.

Calluna Pharma appoints Margrethe Sørgaard as Senior Vice President of Clinical Operations and Pharmacovigilance

First senior executive appointment made following Company launch to oversee strategic development of clinical programs

Neurolentech signs technology access partnership with Kaerus Bioscience to advance neurodevelopmental disorder research

Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes.

Zyme Communications expands UK head office with new facilities at Cambridge Innovation Park

Investment in new headquarters forms part of ongoing company growth plans and supports Zyme’s continued success, following client base and team expansion.

Sphere Fluidics appoints Edward Rayner as Non-Executive Director

Ed Rayner joins Sphere Fluidics as new board member to strengthen the Company’s strategic vision and ambition for commercial growth.

Bio-Rad announces collaboration agreement with Oncocyte to commercialize transplant monitoring with Droplet Digital PCR

Collaboration Aims to Provide Researchers Cutting-Edge Tools to Enable Transformational Monitoring of Key Biomarkers in Solid Tissue Transplants

Metrion Biosciences enhances High Throughput Screening services with access to Enamine compound libraries

Access to compound collection enables greater flexibility and efficiencies in screening and target identification

Preci and Biopredic International partner for higher performance of suspended pooled hepatocytes with extended longevity and large-scale availability

License agreement extends access to culture-stable pooled hepatocyte cell models with increased longevity for use in DMPK and ADME studies

Bio-Rad and Allegheny Health Network Cancer Institute collaborate to advance personalised monitoring of solid tumor cancers with Droplet Digital PCR

Collaboration aims to grow clinical evidence supporting the use of Bio-Rad’s ddPCR™ technology for molecular residual disease monitoring of patients across a range of solid tumor types.

Bio-Rad launches first Ultrasensitive Multiplexed Digital PCR Assay for breast cancer mutation detection in clinical research

Highly Sensitive and Multiplexed Assay for the Detection, Discrimination, and Quantification of Key Mutations in ESR1 Gene for Breast Cancer, Developed for Bio-Rad’s QX600™ Droplet Digital™ PCR System

Key Charpentier/Doudna CRISPR patent upheld by China National Intellectual Property Administration

Dublin, Ireland : ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr.

Bio-Rad launches validated antibodies for rare cell and circulating tumor cell enumeration

Antibodies validated for use with Bio-Rad’s Celselect Slides™ enumeration stain kits to enable immunostaining of captured circulating tumor cells in liquid biopsy samples.